Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma
Open Access
- 15 March 2016
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-10
Abstract
Matrix metalloproteinases (MMPs) are crucially involved in the regulation of multiple stages of cancer progression. Elevated MMP levels have been associated with the development of metastases and poor prognosis in several types of cancer. However, the role of MMPs in osteosarcoma and their prognostic value is still unclear. Available data are conflicting, most likely due to different technical approaches. We hypothesized that in contrast to total mRNA or protein levels frequently analyzed in previous studies the enzymatic activities of MMPs and their inhibitors the tissue inhibitors of matrix metalloproteinases (TIMPs) are closer related to their biological functions. We therefore aimed to evaluate the reliability of different zymography techniques for the quantification of MMP and TIMP activities in osteosarcoma biopsies in order to investigate their distribution, possible regulation and prognostic value. All analyses were done using cryo-conserved osteosarcoma pretreatment biopsies (n = 18). Gene and protein expression of MMPs and TIMPs were analyzed by RT-qPCR and western blot analysis, respectively. Overall MMP activity was analyzed by in situ zymography, individual MMP activities were analyzed by gelatin zymography. Reverse zymography was used to detect and quantify TIMP activities. Strong overall MMP activities could be detected in osteosarcoma pretreatment biopsies with MMP2 and MMP9 as predominant active MMPs. In contrast to total RNA or protein expression MMP2 and MMP9 activities showed significant quantitative differences between good and poor responders. While MMP9 activity was high in the good responder group and significantly decreased in the poor responder group, MMP2 activity showed a reverse distribution. Likewise, significant differences were detected concerning the activity of TIMPs resulting in a negative correlation of TIMP1 activity with MMP2 activity (p = 0.044) and negative correlations of TIMP2 and TIMP3 with MMP9 activity (p = 0.007 and p = 0.006). In contrast to mRNA or protein levels MMP and TIMP activities showed significant differences between the analyzed good and poor responder groups. A shift from MMP9 to predominant MMP2 activity is associated with poor response to chemotherapy suggesting that the ratio of MMP2/MMP9 activity might be a valuable and easily accessible marker to predict the response to chemotherapy in osteosarcoma.Keywords
This publication has 37 references indexed in Scilit:
- Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcomaSurgical Oncology, 2011
- RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasivenessJournal of Orthopaedic Research, 2007
- Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma GroupsJournal of Clinical Oncology, 2005
- Matrix Metalloproteinases Participate in Osteosarcoma InvasionJournal of Surgical Research, 2005
- Suppression of tumor cell invasiveness by hydrolyzable tannins (plant polyphenols) via the inhibition of matrix metalloproteinase-2/-9 activityBiochemical and Biophysical Research Communications, 2005
- Zymographic Techniques for the Analysis of Matrix Metalloproteinases and their InhibitorsBioTechniques, 2005
- Exogenous Tissue Inhibitor of Metalloproteinase‐1 Promotes Endothelial Cell Survival Through Activation of the Phosphatidylinositol 3‐Kinase/Akt PathwayAnnals of the New York Academy of Sciences, 2004
- Expression of Matrix Metalloproteinase-9 in Head and Neck Squamous Cell CarcinomaClinical Cancer Research, 2004
- Stage-IIB osteosarcomas around the kneeThe Journal of Bone and Joint Surgery. British volume, 2002
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002